Trials / Completed
CompletedNCT02288845
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Intra-Cellular Therapies, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITI-007 |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-07-01
- Completion
- 2015-09-01
- First posted
- 2014-11-11
- Last updated
- 2017-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02288845. Inclusion in this directory is not an endorsement.